WHO II and III Gliomas

[1]  Susan M. Chang,et al.  Temozolomide-associated hypermutation in gliomas. , 2018, Neuro-oncology.

[2]  David T. W. Jones,et al.  Novel, improved grading system(s) for IDH-mutant astrocytic gliomas , 2018, Acta Neuropathologica.

[3]  M. J. van den Bent,et al.  Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma , 2018, Journal of Neuro-Oncology.

[4]  T. Mikkelsen,et al.  A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence , 2018, Cell reports.

[5]  W. Wick,et al.  Vaccine Strategies in Gliomas , 2018, Current Treatment Options in Neurology.

[6]  F. Ducray,et al.  Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics , 2018, Journal of Neuro-Oncology.

[7]  Hideo Nakamura,et al.  Prognostic relevance of genetic alterations in diffuse lower-grade gliomas , 2018, Neuro-oncology.

[8]  M. J. van den Bent,et al.  The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis , 2017, Neuro-oncology.

[9]  W. Dinjens,et al.  Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification , 2017, Acta Neuropathologica.

[10]  D. Brachman,et al.  Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study , 2017, The Lancet.

[11]  C. Brennan,et al.  Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma , 2017, Neuro-oncology.

[12]  Zhifeng Shi,et al.  Adult IDH wild-type lower-grade gliomas should be further stratified , 2017, Neuro-oncology.

[13]  Steven J. M. Jones,et al.  Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1 , 2017, Proceedings of the National Academy of Sciences.

[14]  A. Iafrate,et al.  The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. , 2017, Cancer research.

[15]  M. Taphoorn,et al.  Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion. , 2017 .

[16]  I. Flinn,et al.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.

[17]  M. Gilbert,et al.  Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. , 2017, Cancer research.

[18]  Jennie W. Taylor,et al.  Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT , 2017, Acta Neuropathologica.

[19]  Gregory A. Breuer,et al.  2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity , 2017, Science Translational Medicine.

[20]  Susan M. Chang,et al.  Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813 , 2016, Neuro-oncology.

[21]  M. Hassel,et al.  Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. , 2016, The Lancet. Oncology.

[22]  M. Mehta,et al.  Low Levels of Acute Toxicity Associated With Proton Therapy for Low-Grade Glioma: A Proton Collaborative Group Study. , 2016, International journal of radiation oncology, biology, physics.

[23]  Brigitta G. Baumert,et al.  Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma , 2016, The Lancet. Oncology.

[24]  Susan M. Chang,et al.  Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide , 2016, Neuro-oncology.

[25]  T. Tominaga,et al.  Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion , 2016, Journal of Neuro-Oncology.

[26]  Zhen Yang,et al.  Intensity-modulated radiotherapy for gliomas:dosimetric effects of changes in gross tumor volume on organs at risk and healthy brain tissue , 2016, OncoTargets and therapy.

[27]  M. Scorsetti,et al.  Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy , 2016, BMC Cancer.

[28]  Olivier Langlois,et al.  Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas , 2016, Nature Communications.

[29]  Walter J. Curran,et al.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. , 2016, The New England journal of medicine.

[30]  Pieter Wesseling,et al.  Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. , 2016, Neuro-oncology.

[31]  Marion Smits,et al.  Imaging of oligodendroglioma , 2016, The British journal of radiology.

[32]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[33]  I. Mellinghoff,et al.  Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer , 2016, Clinical Cancer Research.

[34]  M. J. van den Bent,et al.  PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients , 2015, Acta Neuropathologica Communications.

[35]  C. Perou,et al.  Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. , 2015, Cell reports.

[36]  W. Vandertop,et al.  Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. , 2015, Cancer research.

[37]  J. Eckel-Passow,et al.  Telomere maintenance and the etiology of adult glioma. , 2015, Neuro-oncology.

[38]  F. Ducray,et al.  Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas , 2015, Neurology.

[39]  F. Ducray,et al.  CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas , 2015, Annals of neurology.

[40]  A. Golby,et al.  The Value of Pre- and Intraoperative Adjuncts on the Extent of Resection of Hemispheric Low-Grade Gliomas: A Retrospective Analysis , 2015, Journal of Neurological Surgery—Part A.

[41]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[42]  Alexander R. Pico,et al.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.

[43]  Volker Hovestadt,et al.  Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities , 2015, Acta Neuropathologica.

[44]  G. Reifenberger,et al.  Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. , 2015, Neuro-oncology.

[45]  W. Curry,et al.  Proton therapy for low‐grade gliomas: Results from a prospective trial , 2015, Cancer.

[46]  Pieter Wesseling,et al.  IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO , 2015, Acta Neuropathologica.

[47]  Lingzhong Meng,et al.  Awake craniotomy to maximize glioma resection: methods and technical nuances over a 27-year period. , 2015, Journal of neurosurgery.

[48]  Susan M. Chang,et al.  Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment , 2015, Acta Neuropathologica.

[49]  K. Aldape,et al.  IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas , 2015, Acta Neuropathologica.

[50]  M. Chamberlain.  Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study , 2015, Journal of Neuro-Oncology.

[51]  Wolfgang A Tome,et al.  Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  W. Dinjens,et al.  Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics , 2014, Journal of Neuro-Oncology.

[53]  F. Ducray,et al.  Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations. , 2014, Neuro-oncology.

[54]  A. Petrilli,et al.  Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review , 2014, Radiation oncology.

[55]  J. Barnholtz-Sloan,et al.  The epidemiology of glioma in adults: a "state of the science" review. , 2014, Neuro-oncology.

[56]  J. E. Scaife,et al.  Clinical and practical considerations for the use of intensity-modulated radiotherapy and image guidance in neuro-oncology. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[57]  Caterina Giannini,et al.  Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  M. Berger,et al.  Role of Surgical Resection in Low- and High-Grade Gliomas , 2014, Current Treatment Options in Neurology.

[59]  Lucia Schwyzer,et al.  Use of fluorescence to guide resection or biopsy of primary brain tumors and brain metastases. , 2014, Neurosurgical focus.

[60]  Jeffrey R. Wilson,et al.  The impact of extent of resection on malignant transformation of pure oligodendrogliomas. , 2014, Journal of neurosurgery.

[61]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[62]  M. J. van den Bent,et al.  MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951 , 2013, Clinical Cancer Research.

[63]  Changxiang Yan,et al.  Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis , 2013, Journal of Neuro-Oncology.

[64]  G. Giles,et al.  Allergy and brain tumors in the INTERPHONE study: pooled results from Australia, Canada, France, Israel, and New Zealand , 2013, Cancer Causes & Control.

[65]  R. Sanyal,et al.  Outcomes, complications, and costs of care of Bosniak IIF, III, and IV cystic renal lesions/malignancies: Data from the largest multi-institutional study to date. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  Geirmund Unsgård,et al.  Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. , 2012, JAMA.

[69]  Jürgen Debus,et al.  First experiences in treatment of low-grade glioma grade I and II with proton therapy , 2012, Radiation oncology.

[70]  N. Rothman,et al.  Genome-wide association study of glioma and meta-analysis , 2012, Human Genetics.

[71]  Kari Stefansson,et al.  A germline variant in the TP53 polyadenylation signal confers cancer susceptibility , 2011, Nature Genetics.

[72]  Volker Seifert,et al.  Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. , 2011, The Lancet. Oncology.

[73]  Melissa Bondy,et al.  Chromosome 7p11.2 (EGFR) variation influences glioma risk. , 2011, Human molecular genetics.

[74]  K. Straif,et al.  Carcinogenicity of radiofrequency electromagnetic fields. , 2011, The Lancet. Oncology.

[75]  K. Aldape,et al.  International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. , 2011, Neuro-oncology.

[76]  Juxiang Chen,et al.  Allergy and risk of glioma: a meta‐analysis , 2011, European journal of neurology.

[77]  M. J. van den Bent,et al.  First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. , 2011, Neuro-oncology.

[78]  R. Guillevin,et al.  Natural history of incidental world health organization grade II gliomas , 2010, Annals of neurology.

[79]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[80]  B. Fisher,et al.  Adult supratentorial low-grade glioma: long-term experience at a single institution. , 2009, International journal of radiation oncology, biology, physics.

[81]  Melissa Bondy,et al.  Genome-wide association study identifies five susceptibility loci for glioma , 2009, Nature Genetics.

[82]  Alexander R. Pico,et al.  Variants in the CDKN2B and RTEL1 regions are associated with high grade glioma susceptibility , 2009, Nature Genetics.

[83]  Mitchel S. Berger,et al.  Operative techniques for gliomas and the value of extent of resection , 2009, Neurotherapeutics.

[84]  R. Guillevin,et al.  Bevacizumab and irinotecan for recurrent oligodendroglial tumors , 2009, Neurology.

[85]  M. Chamberlain,et al.  Bevacizumab for recurrent alkylator‐refractory anaplastic oligodendroglioma , 2009, Cancer.

[86]  M. Chamberlain,et al.  Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma , 2009, Journal of Neuro-Oncology.

[87]  A. Friedman,et al.  Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas , 2008, Clinical Cancer Research.

[88]  Tarik Tihan,et al.  Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium , 2008, Cancer.

[89]  E. Shaw,et al.  Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. , 2008, Journal of neurosurgery.

[90]  M. Berger,et al.  GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME , 2008, Neurosurgery.

[91]  Susan M. Chang,et al.  Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  Mitchel S Berger,et al.  Seizure characteristics and control following resection in 332 patients with low-grade gliomas. , 2008, Journal of neurosurgery.

[93]  U. Hermanto,et al.  Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain? , 2007, International journal of radiation oncology, biology, physics.

[94]  E. Shaw,et al.  A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. , 2006, Cancer research.

[95]  M. J. van den Bent,et al.  1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. , 2006, European journal of cancer.

[96]  Margaret Wrensch,et al.  Epidemiology and molecular pathology of glioma , 2006, Nature Clinical Practice Neurology.

[97]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[98]  M. Piérart,et al.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial , 2005, The Lancet.

[99]  Christos Trantakis,et al.  Intraoperative MRI to guide the resection of primary supratentorial glioblastoma multiforme—a quantitative radiological analysis , 2005, Neuroradiology.

[100]  B. Modan,et al.  Long-Term Follow-up for Brain Tumor Development after Childhood Exposure to Ionizing Radiation for Tinea Capitis , 2005, Radiation research.

[101]  F. Jolesz,et al.  Survival rates in patients with low‐grade glioma after intraoperative magnetic resonance image guidance , 2005, Cancer.

[102]  C. Lui,et al.  Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. , 2005, The British journal of radiology.

[103]  J. Menten,et al.  Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas , 2004, Neurology.

[104]  F. Langmark,et al.  Progress in long-term survival in adult patients with supratentorial low-grade gliomas: a population-based study of 993 patients in whom tumors were diagnosed between 1970 and 1993. , 2003, Journal of neurosurgery.

[105]  B. Scheithauer,et al.  Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  J. Menten,et al.  Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  M. J. van den Bent,et al.  Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  D. Preston,et al.  Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. , 2002, Journal of the National Cancer Institute.

[109]  B. Scheithauer,et al.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  A. Karim,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  W P Dillon,et al.  Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. , 2000, AJNR. American journal of neuroradiology.

[112]  Mitsutoshi Nakamura,et al.  Analysis of Prognostic and Survival Factors Related to Treatment of Low-Grade Astrocytomas in Adults , 2000, Oncology.

[113]  Susan M. Chang,et al.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[114]  K. Skullerud,et al.  Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma , 1998, Journal of Neuro-Oncology.

[115]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[116]  C. Avezaat,et al.  Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery , 1998, Journal of neurology, neurosurgery, and psychiatry.

[117]  H Stepp,et al.  Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. , 1998, Neurosurgery.

[118]  K. Skullerud,et al.  Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  B. Fisher,et al.  Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[120]  A. Karim,et al.  A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. , 1996, International journal of radiation oncology, biology, physics.

[121]  M. Scerrati,et al.  Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres: the role of surgery. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[122]  A. Thiel,et al.  Individual Functional Anatomy of Verb Generation , 1996, NeuroImage.

[123]  A. Bricolo,et al.  Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. , 1995, Surgical neurology.

[124]  T. Cascino,et al.  Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  D. Pickuth,et al.  The management of histologically unverified presumed cerebral gliomas with radiotherapy. , 1994, International journal of radiation oncology, biology, physics.

[126]  Y. Shibamoto,et al.  Supratentorial low‐grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables , 1993, Cancer.

[127]  S. Piantadosi,et al.  Low‐grade cerebral astrocytomas: Survival and quality of life after radiation therapy , 1990, Cancer.

[128]  H. Bloom,et al.  Low grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. , 1990, International journal of radiation oncology, biology, physics.

[129]  J. Cairncross,et al.  Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.

[130]  W. Penfield,et al.  SOMATIC MOTOR AND SENSORY REPRESENTATION IN THE CEREBRAL CORTEX OF MAN AS STUDIED BY ELECTRICAL STIMULATION , 1937 .

[131]  H. Shih,et al.  Neurocognitive effects of proton radiation therapy in adults with low-grade glioma , 2015, Journal of Neuro-Oncology.

[132]  M. Berger,et al.  Survival and low-grade glioma: the emergence of genetic information. , 2015, Neurosurgical focus.

[133]  M. Berger,et al.  Familial gliomas: cases in two pairs of brothers , 2014, Journal of Neuro-Oncology.

[134]  James L. Frazier,et al.  Rapid malignant transformation of low-grade astrocytomas: report of 2 cases and review of the literature. , 2010, World neurosurgery.

[135]  Charles B. Wilson,et al.  Proliferative potential and prognostic evaluation of low-grade astrocytomas , 2005, Journal of Neuro-Oncology.

[136]  A. Peraud,et al.  Clinical Outcome of Supratentorial Astrocytoma WHO Grade II , 1998, Acta Neurochirurgica.

[137]  O. Foerster.  The cerebral cortex in man , 1931 .